Voyager Therapeutics Inc (VYGR) Receives Average Rating of “Buy” from Brokerages

Share on StockTwits

Shares of Voyager Therapeutics Inc (NASDAQ:VYGR) have been assigned an average rating of “Buy” from the fourteen brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $32.50.

Several brokerages have recently commented on VYGR. BTIG Research reiterated a “buy” rating and issued a $32.00 target price on shares of Voyager Therapeutics in a research report on Monday, September 10th. Morgan Stanley reiterated an “equal weight” rating and issued a $27.00 target price on shares of Voyager Therapeutics in a research report on Monday, September 10th. Chardan Capital reiterated a “hold” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday, June 21st. ValuEngine upgraded Voyager Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. Finally, Zacks Investment Research upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th.

In related news, Director James A. Geraghty purchased 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The shares were acquired at an average price of $19.39 per share, with a total value of $58,170.00. Following the acquisition, the director now owns 76,588 shares in the company, valued at approximately $1,485,041.32. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Glenn Pierce purchased 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 12th. The stock was bought at an average cost of $18.44 per share, for a total transaction of $92,200.00. The disclosure for this purchase can be found here. In the last three months, insiders purchased 11,000 shares of company stock worth $205,300. Company insiders own 33.60% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Metropolitan Life Insurance Co. NY raised its stake in Voyager Therapeutics by 53.6% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $177,000 after acquiring an additional 3,157 shares in the last quarter. MetLife Investment Advisors LLC raised its stake in Voyager Therapeutics by 38.6% during the 2nd quarter. MetLife Investment Advisors LLC now owns 10,649 shares of the company’s stock valued at $208,000 after acquiring an additional 2,964 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in Voyager Therapeutics during the 1st quarter valued at $227,000. Thompson Davis & CO. Inc. raised its stake in Voyager Therapeutics by 187.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 11,951 shares of the company’s stock valued at $234,000 after acquiring an additional 7,800 shares in the last quarter. Finally, Hershey Trust Co. bought a new stake in Voyager Therapeutics during the 2nd quarter valued at $284,000. 89.65% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ VYGR traded down $0.33 during mid-day trading on Friday, reaching $18.15. 3,816 shares of the company’s stock traded hands, compared to its average volume of 217,377. Voyager Therapeutics has a 1-year low of $11.54 and a 1-year high of $31.91. The firm has a market cap of $584.50 million, a PE ratio of -6.89 and a beta of 2.89.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, August 7th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). The business had revenue of $2.58 million for the quarter, compared to analyst estimates of $3.00 million. Voyager Therapeutics had a negative net margin of 731.88% and a negative return on equity of 80.68%. equities analysts anticipate that Voyager Therapeutics will post -3.19 EPS for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Further Reading: Average Daily Trade Volume Explained

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.